DB
LXRX icon

Dmitry Balyasny’s Lexicon Pharmaceuticals LXRX Stock Holding History

Dmitry Balyasny’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,433
Closed -$82.6K – 2893
2024
Q1 		$82.6K Buy
+34,433
New +$74K ﹤0.01% 2505
2023
Q1 		– Sell
-38,377
Closed -$73.3K – 2946
2022
Q4 		$73.3K Buy
+38,377
New +$81.7K ﹤0.01% 2290
2022
Q3 		– Sell
-16,363
Closed -$30K – 3086
2022
Q2 		$30K Buy
+16,363
New +$31.2K ﹤0.01% 2425
2018
Q4 		– Sell
-103,741
Closed -$1.11M – 1592
2018
Q3 		$1.11M Buy
+103,741
New +$1.19M 0.01% 1153
2017
Q2 		– Sell
-731,985
Closed -$10.5M – 1621
2017
Q1 		$10.5M Buy
731,985
+13,480
+2% +$200K 0.05% 475
2016
Q4 		$9.94M Buy
718,505
+166,605
+30% +$2.67M 0.05% 479
2016
Q3 		$9.97M Buy
551,900
+370,786
+205% +$5.97M 0.06% 385
2016
Q2 		$2.6M Buy
181,114
+49,070
+37% +$666K 0.02% 639
2016
Q1 		$1.58M Buy
+132,044
New +$1.38M 0.01% 727
2015
Q4 		– Sell
-600,951
Closed -$6.45M – 1348
2015
Q3 		$6.45M Buy
+600,951
New +$6.56M 0.05% 456

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Dmitry Balyasny's LXRX Position: Q2 2024 in Review

Dmitry Balyasny sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2024, closing a stake of 34,433 shares — an estimated $82.6K sold.

Dmitry Balyasny first reported a position in LXRX in Q3 2015 and held it in 10 quarters. The position peaked at $10.5M in Q1 2017. 127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.

  • Dmitry Balyasny reported no remaining Lexicon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 34,433 Lexicon Pharmaceuticals shares in Q2 2024, an estimated $82.6K.
  • Dmitry Balyasny first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 10 quarters.
  • Dmitry Balyasny's Lexicon Pharmaceuticals position peaked at $10.5M in Q1 2017.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.